Current Regulations and Practices for Adverse Event Reporting: Implications for Labeling

Abstract

Safety reporting and postmarketing surveillance is one of the most important responsibilities of a manufacturer following approval of a new drug. New drug products are approved and placed on the market in the United States under the Federal Food Drug and Cosmetic (FD&C) Act. The FD&C Act allows for the approval of drugs that are safe and effective as determined by appropriate experts, qualified by training and experience to make such determinations. Following approval, the sponsor of each drug product is required to collect, monitor, and report to the Food and Drug Administration on all significant new developments with the drug product, including but not limited to, adverse drug experiences received by the company regarding the product. The collection, review, reporting, and assessment of this safety experience information has a great impact on the labeling for a product and the information provided to practitioners on a continuing basis regarding the safe use of a product. Thus, new safety information and the company’s reaction to this information is very important in providing accurate and up-to-date information to medical practitioners.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    FDA Code of Federal Regulations. Subpart B, Postmarketing reporting for adverse drug experiences 314.80.

  2. 2.

    FDA Code of Federal Regulations. Subpart B, Other Postmarketing reports 314.81(b).

  3. 3.

    FDA Code of Federal Regulations. Subpart D, Postmarketing reporting of adverse experiences 600.80.

  4. 4.

    FDA Code of Federal Regulations. Subpart C, Postmarketing reports 314.98.

  5. 5.

    Food and Drug Administration. Expedited Safety Reporting Requirements for Human Drug and Biological Products: Final Rule, 62 FR 52237 Rockville, MD: Food and Drug Administration; October 7, 1997.

    Google Scholar 

  6. 6.

    Johnson JM. Reasonable possibility: Causality and postmarketing surveillance. Drug Inf J. 1992:26:553–558.

    Article  Google Scholar 

  7. 7.

    Food and Drug Administration. Postmarketing Expedited Adverse Experience Reporting for Human Drug and Licensed Biological Products; Increased Frequency Reports, 62 FR 34166. Rockville, MD: Food and Drug Administration; June 25, 1997.

    Google Scholar 

  8. 8.

    Food and Drug Administration. Guideline for Post-Marketing Reporting of Adverse Drug Experiences. Rockville, MD: Food and Drug Administration; March 1992.

    Google Scholar 

  9. 9.

    Kessler DA, et. al. Introducing MedWatch. J Clin Res Drug Dev. 1993;269:183–190.

    Google Scholar 

  10. 10.

    Britt AL. Safety Information Processing at the FDA. Drug Inf J. 1996;30:47–58.

    Article  Google Scholar 

  11. 11.

    Center for Drug Evaluation and Research. CDER Report to the Nation, 1998. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 1997.

    Google Scholar 

  12. 12.

    Department of Health and Human Services Inspector General Report. Review of the Food and Drug Administration’s Handling of Adverse Drug Reaction Reports. Washington, DC: U.S. Department of Health and Human Services; December 1999.

    Google Scholar 

  13. 13.

    Flannery EJ. Reporting Foreign ADRs and ADRs in Phase IV studies, and the Significance of Causality Assessment. Food Drug Cosmetic Law J. 1991;46:43–57.

    Google Scholar 

  14. 14.

    Electronic Reporting of Postmarketing Adverse Drug Reactions; Request for Comments, 63 FR: 59746–59750, 1998.

  15. 15.

    FDA Code of Federal Regulations. Subpart B, IND safety reports 312.32.

  16. 16.

    FDA Code of Federal Regulations. Subpart B, General requirements on content and format of labeling for human prescription drugs 201.56.

  17. 17.

    FDA Code of Federal Regulations. Subpart B, Specific requirements on content and format of labeling for human prescription drugs 201.57.

  18. 18.

    FDA Code of Federal Regulations. Prescription drug advertisements 202.1.

  19. 19.

    FDA Code of Federal Regulations. Subpart B, Specific requirements on content and format of labeling for human prescription drugs 210.57.

  20. 20.

    FDA Code of Federal Regulations. Subpart B, Supplements and other changes to an approved application 314.70.

  21. 21.

    FDA Code of Federal Regulations. Subpart A, Mailing of important information about drugs 200.5.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Michael R. Hamrell PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hamrell, M.R. Current Regulations and Practices for Adverse Event Reporting: Implications for Labeling. Ther Innov Regul Sci 34, 975–980 (2000). https://doi.org/10.1177/009286150003400331

Download citation

Key Words

  • Adverse experience
  • Safety
  • Labeling requirements